13G Filing: Highbridge Capital Management and Novelion Therapeutics Inc. (NVLN)

Page 3 of 6 – SEC Filing

Item 1(a). NAME OF ISSUER:
The name of the issuer is Novelion Therapeutics Inc. (the “Company“).
Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
The Company’s principal executive offices are located at 887 Great Northern Way, Suite 250, Vancouver, B.C., Canada V5T 4T5.
Item 2(a). NAME OF PERSON FILING:
Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
Item 2(c). CITIZENSHIP:
This statement is filed by:

Highbridge Capital Management, LLC

40 West 57th Street, 32nd Floor

New York, New York 10019

Citizenship: State of Delaware

The foregoing person is hereinafter sometimes referred to as the “Reporting Person.”
Item 2(d). TITLE OF CLASS OF SECURITIES:
Common Shares, without par value (the “Common Shares“).
Item 2(e). CUSIP NUMBER:
67001K202
Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
(a) ¨ Broker or dealer registered under Section 15 of the Act,
(b) ¨ Bank as defined in Section 3(a)(6) of the Act,
(c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
(d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
(e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
(g) ¨ Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),

Follow Novelion Therapeutics Inc. (NASDAQ:NVLN)